Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.48 |
| ▸ | AXL | P30530 | 7/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.44 |
| ▸ | GSK3B | P49841 | 8/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273085 | 1.00 | MET (0.48) | METAXLRIPK3MAPK14GSK3B | |
| SCHEMBL764233 | 0.81 | MAPK14 (0.53) | MAPK14GSK3BNR3C2MAPK8MAPK10 | |
| SCHEMBL10273983 | 0.79 | MET (0.43) | METAXLRIPK3MAPK14MAPK10 | |
| SCHEMBL765896 | 0.76 | AXL (0.55) | METAXLMAPK14GSK3BMAPK8 | |
| SCHEMBL4961478 | 0.71 | MAPK14 (0.45) | METAXLRIPK3MAPK14 | |
| Hydrochloric Acid SCHEMBL749696 | 0.71 | MAPK14 (0.44) | METAXLRIPK3MAPK14 | |
| SCHEMBL16105435 | 0.70 | MAPK14 (0.55) | RIPK3MAPK14GSK3BMAPK8MAPK10 | |
| SCHEMBL2401133 | 0.68 | GSK3B (0.74) | MAPK14GSK3BMAPK8MAPK10GSK3A | |
| SCHEMBL2401576 | 0.68 | GSK3B (0.74) | MAPK14GSK3BMAPK8MAPK10GSK3A | |
| SCHEMBL10273430 | 0.67 | MAPK14 (0.41) | MAPK14NR3C2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | MET 1884/4885AXL 3448/4885RIPK3 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.